An observational study in Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2013-11-08.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. · Observational
The primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured adults on antidepressant therapy.
4,845 studies on the registry are indexed under Depressive Disorder; 514 are open to participants now.
This study's enrollment of 48,865 is above the median of 150 across 653 observational studies indexed under Depressive Disorder.
Browse Depressive Disorder studies →Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 289 studies on the registry; 18 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 69 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients will be selected from the MarketScan Commercial Database between January 1, 2004 and September 30, 2008 (the last month of data available)
Exclusion Criteria:
A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
The primary outcome is any use of adjunctive treatment (combined and by class) and the time to initiation of adjunctive treatment (combined and by class).
16 months of medical and prescription drug coverage after the initial antidepressant prescription claim
Time frame: 16 months
sensitivity to cost-sharing will be examined as a function of treatment resistance
16 months of medical and prescription drug coverage after the initial antidepressant prescription claim
Time frame: 16 months
No study locations are listed for this record.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Pharmaceutical Development & Commercialization, Inc.